Preclinical and clinical developments in enzyme-loaded red blood cells: an update

References

• Ihler GM, Glew RH, Schnure FW Enzyme loading of erythrocytes. Proc Natl Acad Sci USA. 1973;70(9):2663–2666. DOI:10.1073/pnas.70.9.2663
   PubMed Web of Science ®Google Scholar
• Zhang E, Phan P, Algarni HA, et al. Red blood cell inspired strategies for drug delivery: emerging concepts and new advances. Pharm Res. 2022;39(11):2673–2698. DOI:10.1007/s11095-022-03328-5
   PubMed Web of Science ®Google Scholar
• Li Y, Raza F, Liu Y, et al. Clinical progress and advanced research of red blood cells based drug delivery system. Biomaterials. 2021;279:121202.
   PubMed Web of Science ®Google Scholar
• Rossi L, Pierigè F, Aliano MP, et al. Ongoing developments and clinical progress in drug-loaded red blood cell technologies. BioDrugs. 2020;34(3):265–272. DOI:10.1007/s40259-020-00415-0
   PubMed Web of Science ®Google Scholar
• Pierigè F, Bigini N, Rossi L, et al. Reengineering red blood cells for cellular therapeutics and diagnostics. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017;9(5):e1454.
   Web of Science ®Google Scholar
• Bax BE. Erythrocytes as carriers of therapeutic enzymes. Pharmaceutics. 2020;12(5). DOI:10.3390/pharmaceutics12050435
   PubMed Web of Science ®Google Scholar
• Glassman PM, Muzykantov VR. Pharmacokinetic and pharmacodynamic properties of drug delivery systems. J Pharmacol Exp Ther. 2019;370(3):570–580.
   PubMed Web of Science ®Google Scholar
• Rossi L, Pierigè F, Bregalda A, et al. Preclinical developments of enzyme-loaded red blood cells. Expert Opin Drug Deliv. 2021;18(1):43–54. DOI:10.1080/17425247.2020.1822320
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Qin S, Ryoo BY, et al. Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma. Ann Oncol Off J Eur Soc Med Oncol. 2018;29(6):1402–1408. DOI:10.1093/annonc/mdy101
   PubMed Web of Science ®Google Scholar
• Gay F, Aguera K, Senechal K, et al. Abstract 4812: arginine deiminase loaded in erythrocytes: a promising formulation for L-arginine deprivation therapy in cancers. Cancer Res. 2016;76(14_Supplement):4812. DOI:10.1158/1538-7445.AM2016-4812
   Google Scholar
• Sanz S, Lizano C, Luque J, et al. In vitro and in vivo study of glutamate dehydrogenase encapsulated into mouse erythrocytes by a hypotonic dialysis procedure. Life Sci. 1999;65(26):2781–2789. DOI:10.1016/S0024-3205(99)00546-9
   PubMed Web of Science ®Google Scholar
• Kosenko EA, Venediktova NI, Kudryavtsev AA, et al. Encapsulation of glutamine synthetase in mouse erythrocytes: a new procedure for ammonia detoxification. Biochem Cell Biol. 2008;86(6):469–476. DOI:10.1139/O08-134
   PubMedGoogle Scholar
• Koleva L, Bovt E, Ataullakhanov F, et al. Erythrocytes as carriers: from drug delivery to biosensors. Pharmaceutics. 2020;12(3):276.
   PubMed Web of Science ®Google Scholar
• Hydery T, Coppenrath VA. A comprehensive review of pegvaliase, an enzyme substitution therapy for the treatment of phenylketonuria. Drug Target Insights. 2019;13:1177392819857089.
   Web of Science ®Google Scholar
• Palynziq [package insert]. Novato (CA): BioMarin Pharmaceutical Inc. 2018.
   Google Scholar
• ir.rubiustx.com [Internet]. Cambridge (MA USA); [cited 2023 May 23]. Available from: https://ir.rubiustx.com/.
   Google Scholar
• Isabella VM, Ha BN, Castillo MJ, et al. Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. Nat Biotechnol. 2018;36(9):857–864. DOI:10.1038/nbt.4222
   PubMed Web of Science ®Google Scholar
• Narasimhan D, Woods JH, Sunahara RK. Bacterial cocaine esterase: a protein-based therapy for cocaine overdose and addiction. Future Med Chem. 2012;4(2):137–150.
   PubMed Web of Science ®Google Scholar
• Khoja S, Lambert J, Nitzahn M, et al. Gene therapy for guanidinoacetate methyltransferase deficiency restores cerebral and myocardial creatine while resolving behavioral abnormalities. Mol Ther Methods Clin Dev. 2022;25:278–296.
   PubMed Web of Science ®Google Scholar
• Zhang G, Huang X, Xiu H, et al. Extracellular vesicles: natural liver-accumulating drug delivery vehicles for the treatment of liver diseases. J Extracell Vesicles. 2020;10(2):e12030. DOI:10.1002/jev2.12030
   PubMed Web of Science ®Google Scholar
• Liu L, Zhang J, Li Z, et al. Enzyme-loaded catalytic macrophage vesicles with cascade amplification of tumor-targeting for oxygenated photodynamic therapy. Int J Nanomedicine. 2021;16:7801–7812.
   PubMed Web of Science ®Google Scholar
• Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8(6):519–530.
   PubMedGoogle Scholar
• Wilder CS, Chen Z, DiGiovanni J. Pharmacologic approaches to amino acid depletion for cancer therapy. Mol Carcinog. 2022;61(2):127–152.
   PubMed Web of Science ®Google Scholar
• Kuo MT, Chen HHW, Feun LG, et al. Targeting the proline–glutamine–asparagine–arginine metabolic axis in amino acid starvation cancer therapy. Pharmaceuticals (Basel). 2021;14(1):72. DOI:10.3390/ph14010072
   PubMedGoogle Scholar
• Backlund PSJ, Chang CP, Smith RA. Identification of 2-keto-4-methylthiobutyrate as an intermediate compound in methionine synthesis from 5’-methylthioadenosine. J Biol Chem. 1982;257(8):4196–4202.
   PubMed Web of Science ®Google Scholar
• Lynggaard LS, Vaitkeviciene G, Langenskiöld C, et al. Asparaginase encapsulated in erythrocytes as second-line treatment in hypersensitive patients with acute lymphoblastic leukaemia. Br J Haematol. 2022;197(6):745–754. DOI:10.1111/bjh.18152
   PubMed Web of Science ®Google Scholar
• erytech.com [Internet]. Lyon (France); [cited 2023 May 23]. Available from: https://erytech.com/.
   Google Scholar
• Sugimura T, Birnbaum SM, Winitz M, et al. Quantitative nutritional studies with water-soluble, chemically defined diets. VIII. The forced feeding of diets each lacking in one essential amino acid. Arch Biochem Biophys. 1959;81(2):448–455. DOI:10.1016/0003-9861(59)90225-5
   PubMed Web of Science ®Google Scholar
• Masaki N, Han Q, Wu NF, et al. Oral-recombinant methioninase lowers the effective dose and eliminates toxicity of cisplatinum for primary osteosarcoma of the mammary gland in a patient-derived orthotopic xenograft mouse model. Vivo. 2022;36(6):2598–2603. DOI:10.21873/invivo.12994
   PubMed Web of Science ®Google Scholar
• Aoki Y, Tome Y, Han Q, et al. Oral-recombinant methioninase converts an osteosarcoma from methotrexate-resistant to -sensitive in a Patient-derived Orthotopic-xenograft (PDOX) mouse model. Anticancer Res. 2022;42(2):731–737. DOI:10.21873/anticanres.15531
   PubMed Web of Science ®Google Scholar
• Kubota Y, Han Q, Hamada K, et al. Long-term stable disease in a rectal-cancer patient treated by methionine restriction with oral recombinant methioninase and a low-methionine diet. Anticancer Res. 2022;42(8):3857–3861. DOI:10.21873/anticanres.15877
   PubMed Web of Science ®Google Scholar
• Han Q, Hoffman RM. Lowering and stabilizing PSA levels in advanced-prostate cancer patients with oral methioninase. Anticancer Res. 2021;41(4):1921–1926.
   PubMed Web of Science ®Google Scholar
• Kubota Y, Han Q, Hamada K, et al. Oral installation of recombinant methioninase-producing Escherichia coli into the microbiome inhibits colon-cancer growth in a syngeneic mouse model. Cancer Genomics Proteomics. 2022;19(6):683–691. DOI:10.21873/cgp.20351
   PubMed Web of Science ®Google Scholar
• Anderson BB, Fulford-Jones CE, Child JA, et al. Conversion of vitamin B 6 compounds to active forms in the red blood cell. J Clin Invest. 1971;50(9):1901–1909. DOI:10.1172/JCI106682
   PubMed Web of Science ®Google Scholar
• Gay F, Aguera K, Sénéchal K, et al. Methionine tumor starvation by erythrocyte-encapsulated methionine gamma-lyase activity controlled with per os vitamin B6. Cancer Med. 2017;6(6):1437–1452. DOI:10.1002/cam4.1086
   PubMed Web of Science ®Google Scholar
• Machover D, Rossi L, Hamelin J, et al. Effects in cancer cells of the recombinant l-methionine gamma-lyase from brevibacterium aurantiacum. encapsulation in human erythrocytes for sustained l-methionine elimination. J Pharmacol Exp Ther. 2019;369(3):489–502. DOI:10.1124/jpet.119.256537
   PubMed Web of Science ®Google Scholar
• Machover D, Goldschmidt E, Mollicone R, et al. Enhancement of 5-fluorouracil cytotoxicity by pyridoxal 5’-phosphate and folinic acid in tandem. J Pharmacol Exp Ther. 2018;366(2):238–243. DOI:10.1124/jpet.118.249367
   PubMed Web of Science ®Google Scholar
• Hoffman RM, Tan Y, Li S, et al. Development of recombinant methioninase for cancer treatment. Methods Mol Biol. 2019;1866:107–131.
   PubMedGoogle Scholar
• Dhankhar R, Gupta V, Kumar S, et al. Microbial enzymes for deprivation of amino acid metabolism in malignant cells: biological strategy for cancer treatment. Appl Microbiol Biotechnol. 2020;104(7):2857–2869. DOI:10.1007/s00253-020-10432-2
   PubMed Web of Science ®Google Scholar
• Endicott M, Jones M, Hull J. Amino acid metabolism as a therapeutic target in cancer: a review. Amino Acids. 2021;53(8):1169–1179.
   PubMed Web of Science ®Google Scholar
• Kumari N, Bansal S. Arginine depriving enzymes: applications as emerging therapeutics in cancer treatment. Cancer Chemother Pharmacol. 2021;88(4):565–594.
   PubMed Web of Science ®Google Scholar
• Chen CL, Hsu SC, Ann DK, et al. Arginine signaling and cancer metabolism. Cancers (Basel). 2021;13(14):3541.
   PubMed Web of Science ®Google Scholar
• Cioni P, Gabellieri E, Campanini B, et al. Use of exogenous enzymes in human therapy: approved drugs and potential applications. Curr Med Chem. 2022;29(3):411–452. DOI:10.2174/0929867328666210713094722
   PubMed Web of Science ®Google Scholar
• Miyazaki K, Takaku H, Umeda M, et al. Potent growth inhibition of human tumor cells in culture by arginine deiminase purified from a culture medium of a Mycoplasma-infected cell line. Cancer Res. 1990;50(15):4522–4527.
   PubMed Web of Science ®Google Scholar
• Patil MD, Bhaumik J, Babykutty S, et al. Arginine dependence of tumor cells: targeting a chink in cancer’s armor. Oncogene. 2016;35(38):4957–4972. DOI:10.1038/onc.2016.37
   PubMed Web of Science ®Google Scholar
• Holtsberg FW, Ensor CM, Steiner MR, et al. Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties. J Control Release Off J Control Release Soc. 2002;80(1–3):259–271. DOI:10.1016/S0168-3659(02)00042-1
   PubMed Web of Science ®Google Scholar
• Ensor CM, Holtsberg FW, Bomalaski JS, et al. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res. 2002;62(19):5443–5450.
   PubMed Web of Science ®Google Scholar
• Tomlinson BK, Thomson JA, Bomalaski JS, et al. Phase I trial of arginine deprivation therapy with ADI-PEG 20 plus docetaxel in patients with advanced malignant solid tumors. Clin Cancer Res An Off J Am Assoc Cancer Res. 2015;21(11):2480–2486. DOI:10.1158/1078-0432.CCR-14-2610
   PubMed Web of Science ®Google Scholar
• Lowery MA, Yu KH, Kelsen DP, et al. A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma. Cancer. 2017;123(23):4556–4565. DOI:10.1002/cncr.30897
   PubMed Web of Science ®Google Scholar
• Hall PE, Lewis R, Syed N, et al. A phase I study of pegylated arginine deiminase (pegargiminase), cisplatin, and pemetrexed in argininosuccinate synthetase 1-deficient recurrent high-grade glioma. Clin Cancer Res An Off J Am Assoc Cancer Res. 2019;25(9):2708–2716. DOI:10.1158/1078-0432.CCR-18-3729
   PubMed Web of Science ®Google Scholar
• Chan PY, Phillips MM, Ellis S, et al. A phase 1 study of ADI-PEG20 (pegargiminase) combined with cisplatin and pemetrexed in ASS1-negative metastatic uveal melanoma. Pigment Cell Melanoma Res. 2022;35(4):461–470. DOI:10.1111/pcmr.13042
   PubMed Web of Science ®Google Scholar
• Tsai HJ, Jiang SS, Hung WC, et al. A phase II study of Arginine Deiminase (ADI-PEG20) in relapsed/refractory or poor-risk acute myeloid leukemia patients. Sci Rep. 2017;7(1):11253. DOI:10.1038/s41598-017-10542-4
   PubMed Web of Science ®Google Scholar
• Ott PA, Carvajal RD, Pandit-Taskar N, et al. Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Invest New Drugs. 2013;31(2):425–434. DOI:10.1007/s10637-012-9862-2
   PubMed Web of Science ®Google Scholar
• Godfrin Y, Goineau PO Erythrocytes containing arginine deiminase. United States patent; US 9,125,876 B2, 2015.
   Google Scholar
• Protasov ES, Borsakova DV, Alexandrovich YG, et al. Erythrocytes as bioreactors to decrease excess ammonium concentration in blood. Sci Rep. 2019;9(1):1455. DOI:10.1038/s41598-018-37828-5
   PubMedGoogle Scholar
• Borsakova DV, Koleva LD, Protasov ES, et al. Ammonium removal by erythrocyte-bioreactors based on glutamate dehydrogenase from Proteus sp. jointly with porcine heart alanine aminotransferase. Sci Rep. 2022;12(1):5437. DOI:10.1038/s41598-022-09435-y
   PubMed Web of Science ®Google Scholar
• Bilder DA, Kobori JA, Cohen-Pfeffer JL, et al. Neuropsychiatric comorbidities in adults with phenylketonuria: a retrospective cohort study. Mol Genet Metab. 2017;121(1):1–8. DOI:10.1016/j.ymgme.2017.03.002
   PubMed Web of Science ®Google Scholar
• van Spronsen FJ, Blau N, Harding C, et al. Phenylketonuria. Nat Rev Dis Prim. 2021;7(1):36. DOI:10.1038/s41572-021-00267-0
   PubMed Web of Science ®Google Scholar
• Elhawary NA, AlJahdali IA, Abumansour IS, et al. Genetic etiology and clinical challenges of phenylketonuria. Hum Genomics. 2022;16(1):22. DOI:10.1186/s40246-022-00398-9
   PubMed Web of Science ®Google Scholar
• Gupta S, Lau K, Harding CO, et al. Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials. EBioMedicine. 2018;37:366–373.
   PubMed Web of Science ®Google Scholar
• Rossi L, Pierigè F, Carducci C, et al. Erythrocyte-mediated delivery of phenylalanine ammonia lyase for the treatment of phenylketonuria in BTBR-Pah(enu2) mice. J Control Release. 2014;194:37–44.
   PubMed Web of Science ®Google Scholar
• Pascucci T, Rossi L, Colamartino M, et al. A new therapy prevents intellectual disability in mouse with phenylketonuria. Mol Genet Metab. 2018;124(1):39–49. DOI:10.1016/j.ymgme.2018.03.009
   PubMed Web of Science ®Google Scholar
• Pipeline. 2009-2023. A late stage and broad pipeline; Bresso (MI Italy); [cited 2023 May 23]; Available from: https://www.erydel.com/pipeline.php/.
   Google Scholar
• ir.rubiustx.com. Rubius Therapeutics Inc. Cambridge (MA USA); 2019. [cited 2023 May 23]; Availbale from: https://ir.rubiustx.com/static-files/4fead852-dd61-4d0a-ac94-6843456f99e2.
   Google Scholar
• Puurunen MK, Vockley J, Searle SL, et al. Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study. Nat Metab. 2021;3(8):1125–1132. DOI:10.1038/s42255-021-00430-7
   PubMedGoogle Scholar
• Vockley J, Sacharow S, Searle S, et al. A phase 1/2a oral placebo-controlled study of SYNB1618 in healthy adult volunteers and subjects with phenylketonuria. J Inherit Metab Dis. 2019;42:13.
   Google Scholar
• Adolfsen KJ, Callihan I, Monahan CE, et al. Improvement of a synthetic live bacterial therapeutic for phenylketonuria with biosensor-enabled enzyme engineering. Nat Commun. 2021;12(1):6215. DOI:10.1038/s41467-021-26524-0
   PubMed Web of Science ®Google Scholar
• Ihler G, Lantzy A, Purpura J, et al. Enzymatic degradation of uric acid by uricase-loaded human erythrocytes. J Clin Invest. 1975;56(3):595–602. DOI:10.1172/JCI108129
   PubMed Web of Science ®Google Scholar
• Magnani M, Mancini U, Bianchi M, et al. Comparison of uricase-bound and uricase-loaded erythrocytes as bioreactors for uric acid degradation. Adv Exp Med Biol. 1992;326:189–194.
   PubMedGoogle Scholar
• Kratzer JT, Lanaspa MA, Murphy MN, et al. Evolutionary history and metabolic insights of ancient mammalian uricases. Proc Natl Acad Sci U S A. 2014;111(10):3763–3768. DOI:10.1073/pnas.1320393111
   PubMed Web of Science ®Google Scholar
• Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet (London, England). 2016;388(10055):2039–2052.
   PubMed Web of Science ®Google Scholar
• FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American college of rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72(6):744–760. DOI:10.1002/acr.24180
   PubMed Web of Science ®Google Scholar
• Botson JK, Baraf HSB, Keenan RT, et al. Expert opinion on pegloticase with concomitant immunomodulatory therapy in the treatment of uncontrolled gout to improve efficacy, safety, and durability of response. Curr Rheumatol Rep. 2022;24(1):12–19. DOI:10.1007/s11926-022-01055-9
   PubMed Web of Science ®Google Scholar
• Geraldino-Pardilla L, Sung D, Xu JZ, et al. Methaemoglobinaemia and haemolysis following pegloticase infusion for refractory gout in a patient with a falsely negative glucose-6-phosphate dehydrogenase deficiency result. Rheumatology. 2014;53:2310–2311. England.
   PubMed Web of Science ®Google Scholar
• Lakra R, Grewal US, Ramadas P. Testing for glucose-6-phosphate dehydrogenase deficiency before rasburicase use for tumor lysis syndrome. Am J Ther. 2023;Publish Ahead of Print. DOI:10.1097/MJT.0000000000001597
   Google Scholar
• Cohen G, Hochstein P. Glutathione peroxidase: the primary agent for the elimination of hydrogen peroxide in erythrocytes. Biochemistry. 1963;2:1420–1428.
   PubMed Web of Science ®Google Scholar
• Mueller S, Riedel HD, Stremmel W. Direct evidence for catalase as the predominant H2O2 -removing enzyme in human erythrocytes. Blood. 1997;90(12):4973–4978.
   PubMed Web of Science ®Google Scholar
• Magnani M, Rossi L, Bianchi M, et al. Role of hexokinase in the regulation of erythrocyte hexose monophosphate pathway under oxidative stress. Biochem Biophys Res Commun. 1988;155(1):423–428. DOI:10.1016/S0006-291X(88)81103-3
   PubMed Web of Science ®Google Scholar
• Ming J, Zhu T, Li J, et al. A novel cascade nanoreactor integrating two-dimensional Pd-Ru nanozyme, uricase and red blood cell membrane for highly efficient hyperuricemia treatment. Small. 2021;17(46):e2103645. DOI:10.1002/smll.202103645
   PubMed Web of Science ®Google Scholar
• Gao D, Narasimhan DL, Macdonald J, et al. Thermostable variants of cocaine esterase for long-time protection against cocaine toxicity. Mol Pharmacol. 2009;75(2):318–323. DOI:10.1124/mol.108.049486
   PubMed Web of Science ®Google Scholar
• Nasser AF, Fudala PJ, Zheng B, et al. A randomized, double-blind, placebo-controlled trial of RBP-8000 in cocaine abusers: pharmacokinetic profile of rbp-8000 and cocaine and effects of RBP-8000 on cocaine-induced physiological effects. J Addict Dis. 2014;33(4):289–302. DOI:10.1080/10550887.2014.969603
   PubMed Web of Science ®Google Scholar
• Leuzzi V, Rossi L, Gabucci C, et al. Erythrocyte-mediated delivery of recombinant enzymes. J Inherit Metab Dis. 2016;39(4):519–530. DOI:10.1007/s10545-016-9926-0
   PubMed Web of Science ®Google Scholar
• Rossi L, Pierigè F, Antonelli A, et al. Engineering erythrocytes for the modulation of drugs’ and contrasting agents’ pharmacokinetics and biodistribution. Adv Drug Deliv Rev. 2016;106(Pt A):73–87. DOI:10.1016/j.addr.2016.05.008
   PubMedGoogle Scholar
• Rossi L, Pierigè F, Agostini M, et al. Efficient cocaine degradation by cocaine esterase-loaded red blood cells. Front Physiol. 2020;11:573492.
   PubMed Web of Science ®Google Scholar
• Chen X, Xue L, Hou S, et al. Long-acting cocaine hydrolase for addiction therapy. Proc Natl Acad Sci U S A. 2016;113(2):422–427. DOI:10.1073/pnas.1517713113
   PubMed Web of Science ®Google Scholar
• Zheng F, Jin Z, Deng J, et al. Development of a highly efficient long-acting cocaine hydrolase entity to accelerate cocaine metabolism. Bioconjug Chem. 2022;33(7):1340–1349. DOI:10.1021/acs.bioconjchem.2c00210
   PubMed Web of Science ®Google Scholar
• Shang L, Jin Z, Wei H, et al. Catalytic activities of a highly efficient cocaine hydrolase for hydrolysis of biologically active cocaine metabolites norcocaine and benzoylecgonine. Sci Rep. 2023;13(1):640. DOI:10.1038/s41598-022-27280-x
   PubMed Web of Science ®Google Scholar
• Zhan M, Hou S, Zhan CG, et al. Kinetic characterization of high-activity mutants of human butyrylcholinesterase for the cocaine metabolite norcocaine. Biochem J. 2014;457(1):197–206. DOI:10.1042/BJ20131100
   PubMedGoogle Scholar
• Hou S, Zhan M, Zheng X, et al. Kinetic characterization of human butyrylcholinesterase mutants for the hydrolysis of cocaethylene. Biochem J. 2014;460(3):447–457. DOI:10.1042/BJ20140360
   PubMedGoogle Scholar
• Chen X, Zheng X, Zhan M, et al. Metabolic enzymes of cocaine metabolite benzoylecgonine. ACS Chem Biol. 2016;11(8):2186–2194. DOI:10.1021/acschembio.6b00277
   PubMed Web of Science ®Google Scholar
• Zheng X, Chen X, Zhang T, et al. Catalytic activities of cocaine hydrolases against the most toxic cocaine metabolite norcocaethylene. Org Biomol Chem. 2020;18(10):1968–1977. DOI:10.1039/C9OB02762A
   PubMed Web of Science ®Google Scholar
• Brimijoin S, Gao Y, Anker JJ, et al. A cocaine hydrolase engineered from human butyrylcholinesterase selectively blocks cocaine toxicity and reinstatement of drug seeking in rats. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2008;33(11):2715–2725. DOI:10.1038/sj.npp.1301666
   PubMed Web of Science ®Google Scholar
• Schindler CW, Justinova Z, Lafleur D, et al. Modification of pharmacokinetic and abuse-related effects of cocaine by human-derived cocaine hydrolase in monkeys. Addict Biol. 2013;18(1):30–39. DOI:10.1111/j.1369-1600.2011.00424.x
   PubMed Web of Science ®Google Scholar
• Cohen-Barak O, Wildeman J, van de Wetering J, et al. Safety, pharmacokinetics, and pharmacodynamics of TV-1380, a novel mutated butyrylcholinesterase treatment for cocaine addiction, after single and multiple intramuscular injections in healthy subjects. J Clin Pharmacol. 2015;55(5):573–583. DOI:10.1002/jcph.450
   PubMed Web of Science ®Google Scholar
• Shram MJ, Cohen-Barak O, Chakraborty B, et al. Assessment of pharmacokinetic and pharmacodynamic interactions between albumin-fused mutated butyrylcholinesterase and intravenously administered cocaine in recreational cocaine users. J Clin Psychopharmacol. 2015;35(4):396–405. DOI:10.1097/JCP.0000000000000347
   PubMed Web of Science ®Google Scholar
• Gilgun-Sherki Y, Eliaz RE, McCann DJ, et al. Placebo-controlled evaluation of a bioengineered, cocaine-metabolizing fusion protein, TV-1380 (AlbuBche), in the treatment of cocaine dependence. Drug Alcohol Depend. 2016;166:13–20.
   PubMed Web of Science ®Google Scholar
• Xing S, Li Q, Xiong B, et al. Structure and therapeutic uses of butyrylcholinesterase: application in detoxification, Alzheimer’s disease, and fat metabolism. Med Res Rev. 2021;41(2):858–901. DOI:10.1002/med.21745
   PubMed Web of Science ®Google Scholar
• Mercimek-Andrews S, Salomons GS. Creatine deficiency disorders. 2009 Jan 15[Updated 2022 Feb 10]. In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH editors. Seattle (WA): University of Washington, Seattle; 1993-2023. GeneReviews® [Internet].
   Google Scholar
• Mercimek-Mahmutoglu S, Stoeckler-Ipsiroglu S, Adami A, et al. GAMT deficiency: features, treatment, and outcome in an inborn error of creatine synthesis. Neurology. 2006;67(3):480–484. DOI:10.1212/01.wnl.0000234852.43688.bf
   PubMed Web of Science ®Google Scholar
• Hanna-El-Daher L, Béard E, Henry H, et al. Mild guanidinoacetate increase under partial guanidinoacetate methyltransferase deficiency strongly affects brain cell development. Neurobiol Dis. 2015;79:14–27.
   PubMed Web of Science ®Google Scholar
• orpha.net [Internet]. 1997-2023; [cited 2023 May 23]. Available from: https://www.orpha.net/.
   Google Scholar
• Mercimek-Mahmutoglu S, Ndika J, Kanhai W, et al. Thirteen new patients with guanidinoacetate methyltransferase deficiency and functional characterization of nineteen novel missense variants in the GAMT gene. Hum Mutat. 2014;35(4):462–469. DOI:10.1002/humu.22511
   PubMed Web of Science ®Google Scholar
• Schulze A. Creatine deficiency syndromes. Mol Cell Biochem. 2003;244(1–2):143–150.
   PubMed Web of Science ®Google Scholar
• Schulze A, Ebinger F, Rating D, et al. Improving treatment of guanidinoacetate methyltransferase deficiency: reduction of guanidinoacetic acid in body fluids by arginine restriction and ornithine supplementation. Mol Genet Metab. 2001;74(4):413–419. DOI:10.1006/mgme.2001.3257
   PubMed Web of Science ®Google Scholar
• Stockler-Ipsiroglu S, van Karnebeek C, Longo N, et al. Guanidinoacetate methyltransferase (GAMT) deficiency: outcomes in 48 individuals and recommendations for diagnosis, treatment and monitoring. Mol Genet Metab. 2014;111(1):16–25. DOI:10.1016/j.ymgme.2013.10.018
   PubMed Web of Science ®Google Scholar
• Hirayasu Y, Morimoto K, Otsuki S. Increase of methylguanidine and guanidinoacetic acid in the brain of amygdala-kindled rats. Epilepsia. 1991;32(6):761–766.
   PubMed Web of Science ®Google Scholar
• Gordon N. Guanidinoacetate methyltransferase deficiency (GAMT). Brain Dev. 2010;32(2):79–81.
   PubMed Web of Science ®Google Scholar
• Iqbal F. Review: human guanidinoacetate n-methyl transferase (GAMT) deficiency: a treatable inborn error of metabolism. Pak J Pharm Sci. 2015;28(6):2207–2211.
   PubMed Web of Science ®Google Scholar
• Sykut-Cegielska J, Gradowska W, Mercimek-Mahmutoglu S, et al. Biochemical and clinical characteristics of creatine deficiency syndromes. Acta Biochim Pol. 2004;51(4):875–882.
   PubMed Web of Science ®Google Scholar
• Stöckler S, Hanefeld F, Frahm J. Creatine replacement therapy in guanidinoacetate methyltransferase deficiency, a novel inborn error of metabolism. Lancet (London, England). 1996;348(9030):789–790.
   PubMed Web of Science ®Google Scholar
• Viau KS, Ernst SL, Pasquali M, et al. Evidence-based treatment of guanidinoacetate methyltransferase (GAMT) deficiency. Mol Genet Metab. 2013;110(3):255–262. DOI:10.1016/j.ymgme.2013.08.020
   PubMed Web of Science ®Google Scholar
• Mercimek-Mahmutoglu S, Pop A, Kanhai W, et al. A pilot study to estimate incidence of guanidinoacetate methyltransferase deficiency in newborns by direct sequencing of the GAMT gene. Gene. 2016;575(1):127–131. DOI:10.1016/j.gene.2015.08.045
   PubMed Web of Science ®Google Scholar
• Schmidt A, Marescau B, Boehm EA, et al. Severely altered guanidino compound levels, disturbed body weight homeostasis and impaired fertility in a mouse model of guanidinoacetate N-methyltransferase (GAMT) deficiency. Hum Mol Genet. 2004;13(9):905–921. DOI:10.1093/hmg/ddh112
   PubMed Web of Science ®Google Scholar
• Sant’anna TB, Araujo NM. Adeno-associated virus infection and its impact in human health: an overview. Virol J. 2022;19(1):173.
   PubMed Web of Science ®Google Scholar
• Shi J, Kundrat L, Pishesha N, et al. Engineered red blood cells as carriers for systemic delivery of a wide array of functional probes. Proc Natl Acad Sci U S A. 2014;111(28):10131–10136. DOI:10.1073/pnas.1409861111
   PubMed Web of Science ®Google Scholar
• Bianchi M, Rossi L, Pierigè F, et al. Engineering new metabolic pathways in isolated cells for the degradation of guanidinoacetic acid and simultaneous production of creatine. Mol Ther Methods Clin Dev. 2022;25:26–40.
   PubMed Web of Science ®Google Scholar
• Rossi L, Fraternale A, Bianchi M, et al. Red blood cell membrane processing for biomedical applications. Front Physiol. 2019;10:1070.
   PubMed Web of Science ®Google Scholar
• Glassman PM, Villa CH, Ukidve A, et al. Vascular drug delivery using carrier red blood cells: focus on rbc surface loading and pharmacokinetics. Pharmaceutics. 2020;12(5). DOI: 10.3390/pharmaceutics12050440
   PubMed Web of Science ®Google Scholar
• Villa CH, Pan DC, Zaitsev S, et al. Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrier. Ther Deliv. 2015;6(7):795–826. DOI:10.4155/tde.15.34
   PubMedGoogle Scholar
• Zhao Z, Kim J, Suja VC, et al. Red blood cell anchoring enables targeted transduction and re-administration of AAV-Mediated gene therapy. Adv Sci (Weinheim, Baden-Wurttemberg, Ger. 2022;9(24):e2201293. DOI:10.1002/advs.202201293
   PubMedGoogle Scholar
• Thangaraju K, Neerukonda SN, Katneni U, et al. Extracellular vesicles from red blood cells and their evolving roles in health, coagulopathy and therapy. Int J Mol Sci. 2020;22(1):153.
   PubMed Web of Science ®Google Scholar
• Yang L, Huang S, Zhang Z, et al. Roles and applications of red blood cell-derived extracellular vesicles in health and diseases. Int J Mol Sci. 2022;23(11):5927.
   PubMed Web of Science ®Google Scholar
• Biagiotti S, Abbas F, Montanari M, et al. Extracellular vesicles as new players in drug delivery: a focus on red blood cells-derived EVs. Pharmaceutics. 2023;15(2):365.
   PubMed Web of Science ®Google Scholar
• Peng B, Nguyen TM, Jayasinghe MK, et al. Robust delivery of RIG-I agonists using extracellular vesicles for anti-cancer immunotherapy. J Extracell Vesicles. 2022;11(4):e12187.
   PubMed Web of Science ®Google Scholar
• Usman WM, Pham TC, Kwok YY, et al. Efficient RNA drug delivery using red blood cell extracellular vesicles. Nat Commun. 2018;9(1):2359. DOI:10.1038/s41467-018-04791-8
   PubMed Web of Science ®Google Scholar
• Do MA, Levy D, Brown A, et al. Targeted delivery of lysosomal enzymes to the endocytic compartment in human cells using engineered extracellular vesicles. Sci Rep. 2019;9(1):17274. DOI:10.1038/s41598-019-53844-5
   PubMedGoogle Scholar
• Haney MJ, Klyachko NL, Harrison EB, et al. TPP1 delivery to lysosomes with extracellular vesicles and their enhanced brain distribution in the animal model of batten disease. Adv Healthc Mater. 2019;8(11):e1801271. DOI:10.1002/adhm.201801271
   PubMed Web of Science ®Google Scholar
• Tang JC, Lee CH, Lu T, et al. Membrane cholesterol enrichment of red blood cell-derived microparticles results in prolonged circulation. ACS Appl Bio Mater. 2022;5(2):650–660. DOI:10.1021/acsabm.1c01104
   PubMedGoogle Scholar
• He M, Yu P, Hu Y, et al. Erythrocyte-membrane-enveloped biomineralized metal-organic framework nanoparticles enable intravenous glucose-responsive insulin delivery. ACS Appl Mater Interfaces. 2021;13(17):19648–19659. DOI:10.1021/acsami.1c01943
   PubMed Web of Science ®Google Scholar
• Rossi L, Bianchi M, Magnani M. Increased glucose metabolism by enzyme-loaded erythrocytes in vitro and in vivo normalization of hyperglycemia in diabetic mice. Biotechnol Appl Biochem. 1992;15(2):207–216.
   PubMed Web of Science ®Google Scholar
• Rossi L, Bianchi M, Fraternale A, et al. Normalization of hyperglycemia in diabetic mice by enzyme-loaded erythrocytes. Adv Exp Med Biol. 1992;326:183–188.
   PubMedGoogle Scholar
• Levene M, Bain MD, Moran NF, et al. Safety and efficacy of erythrocyte encapsulated thymidine phosphorylase in mitochondrial neurogastrointestinal encephalomyopathy. J Clin Med. 2019;8(4):457. DOI:10.3390/jcm8040457
   PubMed Web of Science ®Google Scholar
• Bax BE, Bain MD, Fairbanks LD, et al. A 9-yr evaluation of carrier erythrocyte encapsulated adenosine deaminase (ADA) therapy in a patient with adult-type ADA deficiency. Eur J Haematol. 2007;79(4):338–348. DOI:10.1111/j.1600-0609.2007.00927.x
   PubMed Web of Science ®Google Scholar
• Bax BE, Bain MD, Talbot PJ, et al. Survival of human carrier erythrocytes in vivo. Clin Sci (Lond). 1999;96(2):171–178. DOI:10.1042/cs0960171
   PubMed Web of Science ®Google Scholar
• Coker SA, Szczepiorkowski ZM, Siegel AH, et al. A study of the pharmacokinetic properties and the in vivo kinetics of erythrocytes loaded with dexamethasone sodium phosphate in healthy volunteers. Transfus Med Rev. 2018;32(2):102–110. DOI:10.1016/j.tmrv.2017.09.001
   PubMed Web of Science ®Google Scholar
• Chessa L, Leuzzi V, Plebani A, et al. Intra-erythrocyte infusion of dexamethasone reduces neurological symptoms in ataxia teleangiectasia patients: results of a phase 2 trial. Orphanet J Rare Dis. 2014;9:5.
   PubMed Web of Science ®Google Scholar
• Leuzzi V, Micheli R, D’Agnano D, et al. Positive effect of erythrocyte-delivered dexamethasone in ataxia-telangiectasia. Neurol Neuroimmunol Neuroinflammation. 2015;2(3):e98. DOI:10.1212/NXI.0000000000000098
   PubMedGoogle Scholar
• Bax BE, Levene M, Bain MD, et al. Erythrocyte encapsulated thymidine phosphorylase for the treatment of patients with mitochondrial neurogastrointestinal encephalomyopathy: study protocol for a multi-centre, multiple dose, open label trial. J Clin Med. 2019;8(8):1096. DOI:10.3390/jcm8081096
   PubMed Web of Science ®Google Scholar
• Howard M, Zern BJ, Anselmo AC, et al. Vascular targeting of nanocarriers: perplexing aspects of the seemingly straightforward paradigm. ACS Nano. 2014;8(5):4100–4132. DOI:10.1021/nn500136z
   PubMed Web of Science ®Google Scholar
• Pan D, Vargas-Morales O, Zern B, et al. The effect of polymeric nanoparticles on biocompatibility of carrier red blood cells. PLoS ONE. 2016;11(3):e0152074. DOI:10.1371/journal.pone.0152074
   PubMed Web of Science ®Google Scholar
• Parhiz H, Khoshnejad M, Myerson JW, et al. Unintended effects of drug carriers: big issues of small particles. Adv Drug Deliv Rev. 2018;130:90–112.
   PubMed Web of Science ®Google Scholar
• Mambrini G, Mandolini M, Rossi L, et al. Ex vivo encapsulation of dexamethasone sodium phosphate into human autologous erythrocytes using fully automated biomedical equipment. Int J Pharm. 2017;517(1–2):175–184. DOI:10.1016/j.ijpharm.2016.12.011
   PubMedGoogle Scholar